← Back to Search
Nanomedicine For Uterine Leiomyoma Therapy.
Hazem Ali, G. Kilic, Kathleen Vincent, M. Motamedi, E. Rytting
Published 2013 · Materials Science, Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. METHODS/RESULTS Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and x-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 µM. CONCLUSION This novel approach represents a potential fertility-preserving alternative to hysterectomy.
This paper references
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.
H. L. Wong (2007)
Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.
Z. Rahman (2010)
Catechol-O-Methyltransferase Polymorphism Is Associated With Increased Uterine Leiomyoma Risk in Different Ethnic Groups
A. Al-Hendy (2006)
Drug delivery: Old polymer learns new tracts.
Michael J. Campolongo (2009)
Nanotechnology for delivery of drugs to the brain for epilepsy
Margaret F Bennewitz (2011)
PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency.
Xiangrong Song (2008)
Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells.
D. Zhang (2010)
Uterine leiomyomata: etiology, symptomatology, and management.
V. Buttram (1981)
Epidemiology of myomas.
M. Payson (2006)
Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering.
H. Bunjes (2007)
Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle.
E. Stewart (1994)
Immortalization of Human Uterine Leiomyoma and Myometrial Cell Lines After Induction of Telomerase Activity: Molecular and Phenotypic Characteristics
Sara A. Carney (2002)
Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method.
M. Zambaux (1998)
Electron microscopy of frozen biological suspensions
J. Lepault (1983)
PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
Yolanda Parajó (2010)
Molecular genetics and racial disparities of uterine leiomyomas.
E. R. Othman (2008)
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
J. Fiegel (2004)
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.
N. Mabjeesh (2003)
2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor 1α, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma
J. Ricker (2004)
Nanostructured lipid matrices for improved microencapsulation of drugs.
R. Mueller (2002)
Physicochemical Investigations on Solid Lipid Nanoparticles and on Oil-Loaded Solid Lipid Nanoparticles: A Nuclear Magnetic Resonance and Electron Spin Resonance Study
K. Jores (2004)
Apoptosis in human uterine leiomyomas.
Kristina M Martel (2004)
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
R. Jain (2000)
PLGA - lecithinPEG coreshell nanoparticles for controlled drug delivery
JM Chan (2009)
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier
Benjamin C Tang (2009)
Polymeric nanoparticles for drug delivery.
J. M. Chan (2010)
Drug targeting with nanoparticles
J. Kreuter (2010)
EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy.
R. Garry (2004)
Molecular Bases for the Actions of Ovarian Sex Steroids in the Regulation of Proliferation and Apoptosis of Human Uterine Leiomyoma
H. Matsuo (1999)
Gene Therapy of Uterine Leiomyoma: Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Treatment Inhibits Growth of Human and Rat Leiomyoma Cells in vitro and in a Nude Mouse Model
S.A. Salama (2006)
Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids
S. Salama (2006)
Synthesis and characterization of PEG-based ether-anhydride terpolymers: Novel polymers for controlled drug delivery
J. Fu (2004)
Structure of the Recombinant Alphavirus Western Equine Encephalitis Virus Revealed by Cryoelectron Microscopy
M. Sherman (2010)
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
J. M. Chan (2009)
Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization.
X. Dong (2009)
Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer.
W. Zou (2009)
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
W. Dahut (2006)
Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model.
S. Salama (2006)
New polymeric carriers for controlled drug delivery following inhalation or injection.
Jie Fu (2002)
2-Methoxyestradiol, an Estradiol Metabolite, Inhibits Neointima Formation and Smooth Muscle Cell Growth via Double Blockade of the Cell Cycle
F. Barchiesi (2006)
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
The frequency of uterine leiomyomas.
S. Cramer (1990)
Catechol-O-Methyltransferase Expression and 2-Methoxyestradiol Affect Microtubule Dynamics and Modify Steroid Receptor Signaling in Leiomyoma Cells
S. Salama (2009)
This paper is referenced by
Biological role and therapeutic potential of phytoflavonoids and vitamin D in the treatment of patients with uterine myoma, as well as other promising pharmacological directions
S. N. Buyanova (2018)
Nanobiotechnology in reproduction – pros and cons. A review
M. Zielińska-Górska (2015)
Applications of nanotechnology in reproductive medicine
Céline Jones (2017)
Microvascular and mitochondrial dysfunction in the female F1 generation after gestational TiO2 nanoparticle exposure
P. Stapleton (2015)
Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.
M. Borahay (2016)
Nanotechnology in reproductive medicine: emerging applications of nanomaterials.
N. Barkalina (2014)
Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model
M. Borahay (2020)
New and Emerging Therapies for Uterine Fibroids
K. Fritton (2017)
Nanomedicine applications in women’s health: state of the art
Oliver Lloyd-Parry (2018)
Drug delivery for the treatment of endometriosis and uterine fibroids
D. Friend (2017)
Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs).
Eshan Khan (2019)
The Peep of Nanotechnology in Reproductive Medicine: A Mini-review
M. Razi (2015)
Transport of digoxin-loaded polymeric nanoparticles across BeWo cells, an in vitro model of human placental trophoblast.
N. Albekairi (2015)